Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 3, 2014, Pages 248-256

  Schutz, Fabio A ^a   Buzaid, Antonio C ^a   Sartor, Oliver ^b  

^a Hospital Sao Jose and Beneficencia Portuguesa de Sao Paulo   (Brazil)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cabazitaxel; Docetaxel; Drug toxicity; Prostate cancer

Indexed keywords

ABIRATERONE; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PACLITAXEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; SIPULEUCEL T; TAXANE DERIVATIVE; VINBLASTINE; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; COMPASSIONATE USE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EPIPHORA; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; LACRIMAL DUCT OCCLUSION; LOW DRUG DOSE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; ONYCHOLYSIS; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SKIN MANIFESTATION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); MALE; METABOLISM; MORTALITY; PATHOLOGY; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NEUTROPENIA; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904658346     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.02.003     Document Type: Review

References (71)

1. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101:1642-1649.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Pienta K.J., Smith D.C. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005, 55:300-318. quiz 323-5.
4. Garmey E.G., Sartor O., Halabi S., Vogelzang N.J. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008, 6. 118-22, 127-32.
5. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002, 52:154-179.
6. Diaz M., Patterson S.G. Management of androgen-independent prostate cancer. Cancer Control 2004, 11:364-373.
7. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-8261.
8. Crawford E.D., Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative?. J Clin Oncol 2010, 28:e408.
9. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
10. Basch E.M., Somerfield M.R., Beer T.M., et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 2007, 25:5313-5318.
11. Eisenberger M.A., Simon R., O'Dwyer P.J., et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985, 3:827-841.
12. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993, 71:1098-1109.
13. Raghavan D., Koczwara B., Javle M. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997, 33:566-574.
14. Figg W.D., Ammerman K., Patronas N., et al. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 1996, 14:513-517.
15. Kelly W.K., Scher H.I., Mazumdar M., et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993, 11:607-615.
16. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461-3467.
17. Collette L., Burzykowski T., Carroll K.J., et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005, 23:6139-6148.
18. Armstrong A.J., Garrett-Mayer E., Ou Yang Y.C., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007, 25:3965-3970.
19. Halabi S., Armstrong A.J., Sartor O., et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol 2013, 31:3944-3950.
20. Hussain M., Goldman B., Tangen C., et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009, 27:2450-2456.
21. Hudes G., Einhorn L., Ross E., et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999, 17:3160-3166.
22. Albrecht W., Van Poppel H., Horenblas S., et al. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer 2004, 90:100-105.
23. Osborne C.K., Drelichman A., Von Hoff D.D., Crawford E.D. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep 1983, 67:1133-1135.
24. Tannock I., Gospodarowicz M., Meakin W., et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989, 7:590-597.
25. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
26. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
27. Berry W., Dakhil S., Modiano M., et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002, 168:2439-2443.
28. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
29. Dumontet C., Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999, 17:1061-1070.
30. Terry S., Ploussard G., Allory Y., et al. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009, 101:951-956.
31. Roth B.J., Yeap B.Y., Wilding G., et al. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993, 72:2457-2460.
32. Trivedi C., Redman B., Flaherty L.E., et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000, 89:431-436.
33. Diaz J.F., Andreu J.M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993, 32:2747-2755.
34. Beer T.M., Pierce W.C., Lowe B.A., Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001, 12:1273-1279.
35. Berry W., Dakhil S., Gregurich M.A., Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001, 28:8-15.
36. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
37. Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
38. Caffo O., Sava T., Comploj E., et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 2008, 102:1080-1085.
39. Eymard J.C., Priou F., Zannetti A., et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007, 18:1064-1070.
40. Fizazi K., Le Maitre A., Hudes G., et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007, 8:994-1000.
41. Scher H.I., Jia X., Chi K., et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011, 29:2191-2198.
42. Kelly W.K., Halabi S., Carducci M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012, 30:1534-1540.
43. Galsky M.D., Vogelzang N.J. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 2011, 21:2135-2144.
44. Cisternino S., Bourasset F., Archimbaud Y., et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 2003, 138:1367-1375.
45. Mita A.C., Denis L.J., Rowinsky E.K., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15:723-730.
46. Bissery C., Bouchard H., Riou J.F., et al. Preclinical evaluation of TXD258, a novel taxoid. Proc Am Assoc Cancer Res 2000, 41. [abstr 1364].
47. Pivot X., Koralewski P., Hidalgo J.L., et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008, 19:1547-1552.
48. Berthold D.R., Pond G.R., de Wit R., et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008, 19:1749-1753.
49. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
50. Bahl A., Oudard S., Tombal B., et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013, 24:2402-2408.
51. Oudard S., De Bono J.S., Özgüroglu M., et al. Impact of cabazitaxel (CBZ)+prednisone (P) on overall survival (OS) at 2 yrs and in patients (pts) with aggressive disease: post-hoc analyses of TROPIC trial. Ann Oncol 2012, 23(Suppl. 9):ix307. [abstr 933P].
52. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
53. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
54. Mukherji D., Pezaro C.J., Bianchini D., et al. Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel. J Clin Oncol 2012, 30(Suppl. 5). [abstr 17].
55. van Soest R.J., van Royen M.E., Morrée E.S., et al. Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide: potential mechanism for cross-resistance in castration-resistant prostate cancer (CRPC). J Clin Oncol 2013, 31(Suppl.). [abstr 5064].
56. Bahl A., Masson S., Malik Z.I., et al. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279). J Clin Oncol 2013, 31(Suppl. 6). [abstr 91].
57. Bracarda S., Marchetti P., Gasparro D., et al. Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP). J Clin Oncol 2013, 31(Suppl. 6). [abstr 189].
58. Heidenreich A., Scholz H.J., Rogenhofer S., et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 2013, 63:977-982.
59. Sternberg C.N., Petrylak D.P., Sartor O., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009, 27:5431-5438.
60. Scher H.I., Fizazi K., Saad F., et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012, 30(Suppl. 5). [abstr LBA1].
61. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
62. Baker J., Ajani J., Scotte F., et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009, 13:49-59.
63. Ozguroglu M., Oudard S., Sartor A.O., et al. Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel. J Clin Oncol 2011, 29(Suppl.). [abstr e15131^].
64. Aapro M.S., Bohlius J., Cameron D.A., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
65. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
66. Sanofi-Aventis Taxotere: prescribing information 2012, Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020449s065lbl.pdf [accessed 04.19.12].
67. Sanofi-Aventis Jevtana: prescribing information 2012, Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf [accessed 04.19.12].
68. Esmaeli B., Hortobagyi G., Esteva F., et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002, 13:218-221.
69. Esmaeli B., Amin S., Valero V., et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 2006, 24:3619-3622.
70. Parker C., Nilsson S., Heinrich D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369:213-223.
71. Sartor O., Oudard S., Ozguroglu M., et al. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. J Clin Oncol 2011, 29(Suppl.). [abstr 4525^].